We are Bexson Biomedical.
We are a biopharmaceutical company focused on unlocking the potential of new and existing drugs.

We were born out of the desperate need for potent, non-addictive pain management options.
We began leveraging decades of clinical experience and a goal to transform the care of debilitating medical and mental health conditions. Here is the story…

October 2017
Bexson Biomedical incorporated.

February 2019
Bexson granted FDA orphan designation to treat CRPS with a ketamine therapy.

July 2019
Contracted with Thermo Fisher Scientific to perform GMP manufacturing of Bexson’s ketamine therapy.

December 2019
Completed BB106 ketamine formulation development for subcutaneous delivery.

January 2020
Completed BB106 ketamine formulation development for subcutaneous delivery.

September 2020
Bexson & Stevanato Group co-development agreement for a tamper-resistant wearable infusion device.

November 2020
Filed 5 new provisional patent applications focused on subcutaneous delivery of psychedelic, empathogen and NMDA-receptor antagonist compounds.

December 2020
Launched Project Hermes to develop proprietary formulations of existing psychedelic compounds, designed for subcutaneous delivery.

January 2021
Complete $4.8M Seed Round financing.

February 2021
Initiated IND-enabling animal studies with BB106.

March 2021
Launched Bexson Discovery, developing new compounds targeting the NMDA receptor.

April 2021
Bexson granted USPTO patent on subcutaneous ketamine formulation.

July 2021
Completed $7.3M Series A Financing.

August 2021
Successful Pre-IND FDA guidance for BB106 to treat acute pain.

July 2022
“USPTO Allowance of SeValent™ formulation technology” covering the application of SeValent to ANY molecule regardless of class.

Bexson and Partners are free to explore applications to existing drugs and new chemical entities that have yet to be discovered.

View USPTO Allowance Press Release

September 2022
Stevanato Group and Bexson Collaboration: Developing an On-Body-Platform‍

Jefferies 2022 Investor Conference: Innovation in Mental Health Summit

Robert S. Langer joins the Bexson Scientific Advisory Board

Today
Developing our BB106 non-opioid therapy for pain management and leveraging our SeValent™ platform are the focus of our R&D. Bexson is poised to disrupt the $189 billion (growing to $347 billion by 2030) injectable drug delivery market.

Our SeValent™ technology provides pharmacokinetic solutions for new and existing drugs across a broad range of therapeutic areas.

Bexson Biomedical Downloads

Bexson - Model BB106 - Subcutaneous Ketamine Delivery System for Acute Pain Management

Contact supplier